Swiss Dermatology Network of Targeted Therapies (SDNTT)

• Status: Recruiting
• Trial end date: 2033-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy.

The registry will also evaluate safety clinical outcomes and health related quality of life.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swiss Dermatology Network for Targeted Therapies
• Treatments: Adalimumab; Cyclosporine; Cyclosporins; Etanercept; Infliximab; Methotrexate; Ustekinumab

Criteria

Inclusion Criteria:

• Patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist,

• age ≥ 18,

• Being administered a specific biologic/conventional systemic drug for the first time

• Sufficient language skills (German, French, Italian and English) for the informed consent to participate

• Informed consent to participate

Exclusion Criteria:

• Lack of informed consent

• Patients being participants of clinical trials at the day of registration to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analyzed separately)